Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rare diseases: Opportunistic or Philanthropic?

This article was originally published in Scrip

Executive Summary

With special incentives associated with orphan drug status and the technological advances underpinned by better understanding of the underlying genetics, it is not surprising that rare diseases have become an increasingly attractive target for the pharma and biotech companies. However, while most companies' entry into the orphan drug field has been primarily motivated by the potential for technology breakthroughs and the business opportunity, the societal impact is also a potential major driver.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts